HLA-DRB9

Last update 08 May 2025

Basic Info

Synonyms

D6S206, D6S206E, HLA-DR1BL

+ [3]

Introduction-

100 Clinical Results associated with HLA-DRB9

100 Translational Medicine associated with HLA-DRB9

0 Patents (Medical) associated with HLA-DRB9

Literatures (Medical) associated with HLA-DRB9

06 Feb 2025·Current Medicinal Chemistry

Integrative Multi-omics Analysis and Mendelian Randomization Reveal Potential Therapeutic Targets and their Stratification in Lung Squamous Cell Carcinoma

Article

Author: Lai, Xuntao ; Chen, Xiaoyi ; Chang, Zhenglin ; Chen, Youpeng ; Li, Enzhong ; Xie, Yifei ; Cheng, Zhangkai J. ; Sun, Junquan ; Sun, Baoqing

Background:Lung Squamous Cell Carcinoma (LUSC), a major subtype of non-small cell lung cancer, presents significant treatment challenges due to limited targeted therapy options. This study aims to identify novel therapeutic targets to improve therapeutic strategies for LUSC.Methods:By employing bulk RNA sequencing, Weighted Gene Co-expression Network Analysis (WGCNA), survival analysis, and Mendelian Randomization (MR), we pinpointed genes with prognostic relevance to LUSC. These genes were further scrutinized for their therapeutic potential through LASSO regression, Protein-Protein Interaction (PPI) network analysis, and immune infiltration assessments. To delve into the roles and cell-specific expressions of these genes within the LUSC microenvironment, pathway enrichment analysis, single-cell RNA sequencing (scRNA-seq), and pseudotime analysis were conducted.Results:Our integrative approach identified 23 prognostically significant therapeutic targets, categorized into tier-one, tier-two, and tier-three genes based on their potential therapeutic relevance. Functional enrichment analyses highlighted the significant role of these genes in immune response regulation, particularly in T-cell receptor signaling and the complement system. scRNA-seq analysis revealed cell-type-specific expression patterns and pseudotime analysis provided insights into cellular heterogeneity and developmental trajectories in LUSC.Conclusions:In this study, we identified 3 tier-one genes (MCM6, C4B, CTC-463A16.1), 7 tier-two genes (C4A, HLA-DRB9, LIMS2, LINC00654, MYO7B, SIGLEC5, TIE1), and 13 tier-three genes (AC007743.1, AC147651.4, ALDH2, BTN3A2, BTNL9, CCR1, GIPC3, HLA-DQB1, ICAM5, LIMD1, PM20D1, RP11-302L19.3, RP11-768F21.1).

01 Nov 2024·Arthritis & Rheumatology

A Genome‐Wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome

Article

Author: Alarcón-Riquelme, Marta E ; Martinez-Bueno, Manuel ; Zuo, Yu ; Espinosa, Gerard ; Meroni, Pier Luigi ; Casares-Marfil, Desiré ; Radstake, Timothy ; Wallace, Chris ; Radstake, Timothy ; James, Judith A ; van den Hoogen, Lucas L. ; Reales, Guillermo ; van den Hoogen, Lucas L ; Casares-Marfil, Desire ; Espinosa, Gerard ; Guthridge, Joel ; Pons-Estel, Guillermo ; Martínez-Bueno, Manuel ; Knight, Jason S ; Wallace, Chris ; Sawalha, Amr H ; Reales, Guillermo ; Meroni, Pier Luigi ; Borghi, Maria Orietta ; Knight, Jason S. ; Cervera, Ricard ; Alarcon-Riquelme, Marta E. ; Cervera, Ricard ; Martin, Javier ; Guthridge, Joel ; Martin, Javier ; PRECISESADS Clinical Consortium ; Zuo, Yu ; James, Judith A. ; Sawalha, Amr H.

ObjectivePrimary antiphospholipid syndrome (PAPS) is a rare autoimmune disease characterized by the presence of antiphospholipid antibodies and the occurrence of thrombotic events and pregnancy complications. Our study aimed to identify novel genetic susceptibility loci associated with PAPS.MethodsWe performed a genome‐wide association study comprising 5,485 individuals (482 affected individuals) of European ancestry. Significant and suggestive independent variants from a meta‐analysis of approximately 7 million variants were evaluated for functional and biological process enrichment. The genetic risk variability for PAPS in different populations was also assessed. Hierarchical clustering, Mahalanobis distance, and Dirichlet Process Mixtures with uncertainty clustering methods were used to assess genetic similarities between PAPS and other immune‐mediated diseases.ResultsWe revealed genetic associations with PAPS in a regulatory locus within the HLA class II region near HLA‐DRA and in STAT1‐STAT4 with a genome‐wide level of significance; 34 additional suggestive genetic susceptibility loci for PAPS were also identified. The disease risk allele near HLA‐DRA is associated with overexpression of HLA‐DRB6, HLA‐DRB9, HLA‐DQA2, and HLA‐DQB2 in immune cells, vascular tissue, and nervous tissue. This association is independent of the association between PAPS and HLA‐DRB1*1302. Functional analyses highlighted immune‐related pathways in PAPS‐associated loci. The comparison with other immune‐mediated diseases revealed a close genetic relatedness to neuromyelitis optica, systemic sclerosis, and Sjögren syndrome, suggesting co‐localized causal variations close to STAT1‐STAT4, TNPO3, and BLK.ConclusionThis study represents a comprehensive large‐scale genetic analysis for PAPS and provides new insights into the genetic basis and pathophysiology of this rare disease.

image

01 Nov 1996·Human ImmunologyQ4 · MEDICINE

The HLA-DRB9 gene and the origin of HLA-DR haplotypes

Q4 · MEDICINE

Article

Author: Rafael Gongora ; Jan Klein ; Felipe Figueroa

HLA-DRB9 is a gene fragment consisting of exon 2 and flanking intron sequences. It is located at the extreme end of the DRB subregion, whose other end is demarcated by the DRB1 locus. We sequenced approximately 1400 base pairs of the segment encompassing the DRB9 locus from eight human haplotypes (DR1, DR10, DR2, DR3, DR5, DR6, DR8, and DR9, the DR4 and DR7 having been sequenced by others earlier), as well as two chimpanzee, five gorillas, one orangutan and one macaque haplotype. The analysis of these sequences indicates that the DRB9 locus, which we estimate to be more than 58 million years (my) old, has been coevolving with the DRB1 locus for the last 4.2 my. As a consequence of this coevolution, the human DRB9 alleles fall into groups that correlate with the DRB1 allelic groups and with the gene organization of the human haplotypes. This observation implies that the present-day HLA-DR haplotype groups (DR1, DR51, DR52, DR8, and DR53) were founded more than 4 my ago and have remained intact (barring minor internal rearrangements that did not recombine the DRB1 and DRB9 genes) for this period of time. The haplotypes have been transmitted during speciations from ancestral to emerging species just like allelic lineages at the DRB1 locus. Thus not only allelic but also haplotype polymorphism evolves trans-specifically.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

HLA-DRB9

Basic Info

Related

Analysis